These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2860886)

  • 21. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.
    Cohen BM; Tsuneizumi T; Baldessarini RJ; Campbell A; Babb SM
    Psychopharmacology (Berl); 1992; 108(3):338-44. PubMed ID: 1355924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locomotion and stereotyped behaviours induced by 1-amino-3,5-dimethyladamantane (D 145) and apomorphine in the rat: a comparison.
    Ljungberg T
    J Pharm Pharmacol; 1986 Jul; 38(7):520-5. PubMed ID: 2875153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels.
    Antkiewicz-Michaluk L; Karolewicz B; Michaluk J; Vetulani J
    Eur J Pharmacol; 1995 Dec; 294(2-3):459-67. PubMed ID: 8750706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the potential neuroleptic peptide des-tyrosine-gamma-endorphin and haloperidol on apomorphine-induced behavioural syndromes in rats and mice.
    Nickolson VJ; Berendsen HH
    Life Sci; 1980 Oct; 27(15):1377-85. PubMed ID: 7192353
    [No Abstract]   [Full Text] [Related]  

  • 26. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
    Costall B; Naylor RJ; Owen RT
    Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
    Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
    Lal H; Gianutsos G; Puri SK
    Life Sci; 1975 Jul; 17(1):29-34. PubMed ID: 238089
    [No Abstract]   [Full Text] [Related]  

  • 29. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphine and [D-Met2,Pro5]enkephalinamide do not show specific neuroleptic activity.
    Sineger E; Horváth K; Miglécz E; Tarnawa I; Andrási F; Székely JI
    Eur J Pharmacol; 1982 Jun; 80(4):359-68. PubMed ID: 6125401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
    Gnegy M; Uzunov P; Costa E
    J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
    [No Abstract]   [Full Text] [Related]  

  • 35. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
    Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of raclopride on vacuous jaw movements in rats following acute administration.
    Steinpreis RE; Kaczmarek HJ; Harrington A
    Physiol Behav; 1996 Jul; 60(1):253-6. PubMed ID: 8804672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between pD2 and pA2 of neuroleptics.
    Morgenstern R; Strutz G
    Acta Biol Med Ger; 1980; 39(1):133-9. PubMed ID: 6106991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine.
    Nakamura S; Engel J; Goldstein M
    Commun Psychopharmacol; 1978; 2(3):185-90. PubMed ID: 29742
    [No Abstract]   [Full Text] [Related]  

  • 39. Chromopharmacological study of neuroleptics. III. Circadian rhythm of brain susceptibility to haloperidol.
    Nagayama H; Takagi A; Sakurai Y; Yoshimoto S; Nishiwaki K; Takahasi R
    Psychopharmacology (Berl); 1979 May; 63(2):131-5. PubMed ID: 112631
    [No Abstract]   [Full Text] [Related]  

  • 40. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins.
    Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K
    Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.